<SEC-DOCUMENT>0001129928-13-000020.txt : 20130429
<SEC-HEADER>0001129928-13-000020.hdr.sgml : 20130427
<ACCEPTANCE-DATETIME>20130429140853
ACCESSION NUMBER:		0001129928-13-000020
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130429
FILED AS OF DATE:		20130429
DATE AS OF CHANGE:		20130429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		13790792

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6K FORM
<TEXT>
<html>
<head>
    <title>form6-k.htm</title>
    <!--Licensed to: Oncolytics Biotech Inc-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<br>
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Form 6-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Report of Foreign Private Issuer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Rule&#160;13a-16 or 15d-16</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the month of&#160;April 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission File Number 000-31062</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Translation of registrant&#8217;s name into English)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Suite&#160;210, 1167 Kensington Crescent NW</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Calgary, Alberta, Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Address of principal executive offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form&#160;20-F&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#254;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form&#160;40-F&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">No&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#254;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NUMBER</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="69%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">News Release Dated April 29, 2013: Oncolytics Biotech&#174; Inc. to Present at 12th Annual Needham Healthcare Conference</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="4" valign="top" width="39%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Registrant)</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date:&#160;&#160;April 29, 2013</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">/s/&#160;&#160;Kirk Look</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Kirk Look</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1 CHARTER
<SEQUENCE>2
<FILENAME>ex99.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
    <title>ex99.htm</title>
    <!--Licensed to: Oncolytics Biotech Inc-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><img src="onclogo.jpg" alt=""></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">210, 1167 Kensington Cr. N.W.</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Calgary, Alberta</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>

<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">MEDIA ADVISORY</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> Inc. to Present at 12<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Annual Needham Healthcare Conference</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CALGARY, AB, April 29, 2013 ---</font> Dr. Alan J. Tuchman, Senior Vice President, Medical &amp; Clinical Affairs and Chief Medical Officer of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 12<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Annual Needham Healthcare Conference on <font style="DISPLAY: inline; FONT-WEIGHT: bold">Tuesday, April 30</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-WEIGHT: bold">th</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">, 2013 at 12:10 p.m. ET</font>.<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>The conference will take place on April 30<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> and May 1<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">st</font> at the Westin Grand Central Hotel in New York, NY.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A live audio link to the webcast presentation is available at: <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://wsw.com/webcast/needham58/oncy/</font> or on the company&#8217;s website at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com/presentations</font>.&#160;&#160;&#160;It is recommended that listeners log on 10 minutes in advance of the presentation to register and download any necessary software.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">An audio replay will be accessible approximately one hour following the presentation on the Oncolytics website.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.&#160;&#160;Oncolytics&#8217; clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font>, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">The presentation and webcast times are subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company&#8217;s control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements</font>.<font style="DISPLAY: inline; TEXT-DECORATION: underline"> S</font><font style="FONT-STYLE: italic; DISPLAY: inline">uch risks and uncertainties include, among others, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company&#8217;s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR FURTHER INFORMATION PLEASE CONTACT:</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 0.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Equicom Group</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nick Hurst</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">300 5<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Ave. SW, 10<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Calgary, Alberta&#160;&#160;T2P 3C4</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel: 403.218.2835</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax: 403.218.2830</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">nhurst@equicomgroup.com</font></font></div>
</td>
<td valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 0.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dian Griesel, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Susan Forman</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">396 West Broadway, 2<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">New York, NY&#160;&#160;10012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel:&#160;&#160;212.825.3210</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax:&#160;&#160;212.825.3229</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">sforman@dgicomm.com</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-30-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>onclogo.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 onclogo.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X0E(17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````0````<@$R``(````4````@H=I``0````!````E@```+8```$L````
M`0```2P````!4&%I;G0N3D54('8U+C`P`#(P,#@Z,#4Z,C(@,34Z,CDZ,S@`
M``*@`@`$`````0```\"@`P`$`````0```.$`````````!@$#``,````!``8`
M``$:``4````!```!!`$;``4````!```!#`$H``,````!``(```(!``0````!
M```!%`("``0````!```(+`````````!(`````0```$@````!_]C_X``02D9)
M1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$
M``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,
M#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(
M`"8`H`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"
M!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($
M`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#
M!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&
M!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S
M-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/55C]2^
ML3,?,_9O3\=_4^I@!S\>DAK:VGZ+LS)?^BQMWYG^%_X-%^L?4KNF])MOQFA^
M786T8C#WNN<*:/\`->_U%/HG1Z.D8+<:LFVYY-F5DNU?=<[W77VN^DYSW)I)
M)H:=RIH[_KT[WBKI=0.OI.?>YP_DNM:QK/\`P-*GZRW8V37A]?PSTRVXAE&2
M'BW%L<>*VY(#/1M?^95D,8MY`S<+%S\6W#S*VW8][=ME;N"#_K[7)<)&Q/U4
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M[/HUTX=3_.R+K?\`HUVUK*HQ.HGK?7.H=),9^+E,!Q["6U9-+J:G.Q7S[:K=
M_OQLK_!6?SGZ&Q=!]7^E6=,P7-R;!=G95CLG.N:(#KK/I[/^"K;MJJ_X-B:K
MK+[,_P"QG%>T>M91ZG,>FSU6W/9M]M-WT&6?03*T%Z:D_P",EH?5&]F3D]:R
M:V65-NS`[T[FEEC3Z-#;*[*W?1?7:U]:I=-_98R,P?6P5?M0WV;'9X'H^A/Z
MN.FNR?U;[/L^DVG]-ZG])]ZZG)R319C,%;K/M-OI%S>&#T[;O4?_`"/T/I_]
M<4<_+=B8_K-J=<2]C(;PT/<&>K:[W;**MWJ76;?T=:/#IO\`+X:*<SJ0>[ZJ
MY#?JN&L=Z3AB#'`9^=^E^S_1VV?SOI?\(L[_`+!3TN"RAEVSZ&V.H"R/W?\`
ME'[=ZG_7O4718.<[+?>PU%@H>&BUIW56`M;9NHMAGJ;-WIV^S^=3?:\G]I?8
M_0'I>GZOK[C$3LV;?3V^K_(]3Z"1`-'3]W93S^8WJCO\7%S>J!YSSAN%H?K9
MW]/U-O\`A?2V>I_PBV>F=9Z3>S'Q*,RFS(-;0*FO!<2UNY_M^E[6M1^I=0=@
MMH(I-WKV^D2#`8-EEWJ6.AWM_0^G_7L5JI_J5L?I[FAVAD:C\UVB(%'0[`#5
M3S'7,;)Z+E5Y?1+1C.ZSD,Q,FES/4J;==(KZI75+?3R*MOZ?_`Y?^&_2+8P.
MA=.PL!^#Z8R*[B7Y3\B+'WV.ULNRG/\`YU[W?^HT3IW479K0\UBC<W=Z+W'U
MF:QLR*-GZ&S]_P#2V(N5E.Q[,9C:7W?:+342R/8!7;?ZC]WMV?H?3_ZXD`-3
MT*GG>G=%Z/9]9NLX]F!COHJKQ#56ZEA8TO;=ZOI,<WTV[]OZ38K7UI'ZWT"!
MQU*O@<?H[_!;&!E.S,87NJ?02^QGIV:.'IO?3+OZ_I[U80$1PT.NO_=*>;^L
MF_\`:N`>HA[OJ^&O^TA@<:_7D>A^T&U>[['_`%_U;U?Z0KW2S]6/M3OV.,3[
M0:_>[$#/H`C1[Z!M^G^8KV/E&[(RJ36Y@QGM8'NX?NKKNWL_J^KZ?]A4^H]:
MLP+KV?8[KZZ:&W"VL%P+WFYM>/M:USO=Z'\[[_2]6OUO39[TM`>+]BGGLRGH
M[,_.O;G]-R;;+7.MHZO6'VL</8ZC&O=978S$;M_0U?9K_P#@UT'U9O%_1Z7M
MP?V:P%[68^H;M#C%M(<VJST;OYROU*JE=SLHX>*_(%3[RR/T=8EWN<&;O^+K
MW>I;_P`$I8MYOK+SZ9@Q^B?ZC?\`/V5I"-2W_!3_`/_1]56;U[]@_8'?M[T/
ML<_]J(C=_P`%^?ZO_%?I%\SI(2V.WUV4^Z,H^J3JM^-D]79A]JZAU'T8_D_H
MG>S^VMKZL_\`-3T[/^;_`*.^?T\3Z_\`Z$?:/UO_`+=7SBDHX[CY?I_W*?M?
MJI)?*J2E0_522^54DE/U4DOE5))3]5)+Y5224_522^54DE/U4DOE5))3]5)+
MY5224_522^54DE/_V?_B#%A)0T-?4%)/1DE,10`!`0``#$A,:6YO`A```&UN
M=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94`````$E%0R!S4D="````
M``````````````#VU@`!`````-,M2%`@(```````````````````````````
M````````````````````````````````````$6-P<G0```%0````,V1E<V,`
M``&$````;'=T<'0```'P````%&)K<'0```($````%')865H```(8````%&=8
M65H```(L````%&)865H```)`````%&1M;F0```)4````<&1M9&0```+$````
MB'9U960```-,````AG9I97<```/4````)&QU;6D```/X````%&UE87,```0,
M````)'1E8V@```0P````#')44D,```0\```(#&=44D,```0\```(#&)44D,`
M``0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="($E%0S8Q.38V+3(N,0``
M````````````$G-21T(@245#-C$Y-C8M,BXQ````````````````````````
M``````````````````````````````````````````!865H@````````\U$`
M`0````$6S%A96B``````````````````````6%E:(````````&^B```X]0``
M`Y!865H@````````8ID``+>%```8VEA96B`````````DH```#X0``+;/9&5S
M8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H```````````````6245#
M(&AT='`Z+R]W=W<N:65C+F-H````````````````````````````````````
M`````````````````````````&1E<V,`````````+DE%0R`V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``````````````+DE%
M0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``
M``````````````````````````!D97-C`````````"Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ```````````````L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````
M````````````````````````````=FEE=P``````$Z3^`!1?+@`0SQ0``^W,
M``03"P`#7)X````!6%E:(```````3`E6`%````!7'^=M96%S``````````$`
M```````````````````````"CP````)S:6<@`````$-25"!C=7)V````````
M!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!``$4`2@!/`%0`60!>`&,`
M:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`L@"W`+P`P0#&`,L`T`#5
M`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K`3(!.`$^`44!3`%2`5D!
M8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!T0'9`>$!Z0'R`?H"`P(,
M`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8`J("K`*V`L$"RP+5`N`"
MZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#E@.B`ZX#N@/'`],#X`/L
M`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V!,0$TP3A!/`$_@4-!1P%
M*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2`99!FH&>P:,
M!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^`@+"!\(
M,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)9`EY"8\)I`FZ"<\)Y0G[
M"A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@`N8"[`+R`OA"_D,
M$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-C@VI#<,-W@WX#A,.+@Y)
M#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$`D0)A!#$&$0?A";$+D0
MUQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3`Q,C$T,38Q.#
M$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X%9L5O17@%@,6)A9)%FP6
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MUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB
M/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G02E!:D&L0>Y",$)R0K5"
M]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C7
M21U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/
M24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"
M5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<
MUETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K
M9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]K
MIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9PX'$Z<95Q\')+<J9S`7-=
M<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[
MPGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!:X'-@C""DH+T@U>#NH0=
MA("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-
M,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.339.VE""4BI3TE5^5R98T
MEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?
M^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFI
MJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!UL.JQ8+'6LDNRPK,XLZZT
M);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$
MOO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)
MN<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1/-&^TC_2P=-$T\;42=3+
MU4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@
MO>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&
M[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY
M./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____;`$,``0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`'`!X`,!(@`"$0$#
M$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_Q`"U$``"`0,#
M`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S
M8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#
M`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!
M`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q
M%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(
MR<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/[^
M****`"BBB@`HKA_B'\2/`_PH\+:IXX^(WBK0/!?A'18&N=4\0^)=5L]'TNSC
M7[JO=WLT,;W$[$0VEK%YES=W#QV]O#)+(JG\"/VE_P#@X"^%_A2YO_#G[,WP
MZO/B?J%N9;=/'GC>:Z\+>"S.&"BYTOP_%'_PE7B&SSM`%Z_A%YMP>T>=$#/X
M6;\29/D5/VF9XRE0;CS0HJ7/B*D=-8TE9Z7UU_,UI4:E:7+3BY6W?1']%]%?
MP^ZK_P`%._\`@J7^TKJMSI_PSU_QE"D[L/\`A%O@!\+4G:U$I!2*+4K#1_$?
MBZ*)0T:+)/KSW&X;?,>1Z?%X`_X+>:^HU(7'[>48G`<*_C_XE^'R%;)'_$NE
M\2:68?I]DB8?Q*,KGY!^)6&J^]E_#V?X^E_S^I83EAK:UM97OKVU5O3H^I27
MQ5:2[>]?M^5_N^X_M_HK^'.Z^(?_``6E^!*G5M9U#]L_3K*S'FSZCXMTCQG\
M0M"AB3.YKJ?Q)I_BC1VB`1FD-S*2%)9E"Q$CW#X+_P#!?']J;P%?6^E?'#P3
MX+^,&C6\GDZC-'IY^'7CA6#+',1>Z5!/X:<PXD86DOA.*:5T,,EVB%YDJAXG
M90JL:69Y?FN4.6]3%X9NE&UMW&U26ZNZ=*:5_>MI=_4*DOX=2E.V_O6MMZI]
M?N/['**_.C]DS_@J#^RO^UV]GH'A#Q3+X)^)-PBY^&/Q`^R:)XCN[@(6F3P[
M=+<SZ+XK1"DC"/1-0GU2.V47%]I=B"R+^B]??8#,<%F>'ABL!B:6*P\_AJT9
M<T7^3^](Y)PE3DX33C);IA111780%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%?$W[;7[<GPF_8C^&8\9^/9O
M[9\5:VEW:_#[X<Z7=0QZ_P",M7@1`^QG60:9H&G&:&;6]?N(9+>QB:.WMXK[
M5KK3],O/;?VA_CSX'_9H^$'C;XT?$6[^S>%_!6CS7\L$+QC4-8U.1DMM%\.Z
M3%(52;5=>U.>VTVQ1F6))IQ-</%:Q331_P`57@_PS^T/_P`%?OVS+^^U74)[
M&#4)EU#Q'K)2XNO"_P`&_A597VVRTC2H'>-6GCAF.G:/8;H+CQ+XBN;C6=3>
M,SZWJ4/PW%_%%?*5A<LRFC]<SW,Y^RPE"/O>P3Y;8BK&VRYO<BW%2M)\RL=>
M$H1K2G.II2I1YY^>NBW5KOK9^A)K'B#]N3_@K]\<O[.L8;S7-/TV[-S:Z#97
M%SHGP;^#VAW4\D$=UJ%PYFM8+GR&D1]2NAJ?BWQ"\,\%BMT%AL(/Z!_V3?\`
M@B#^S+\$[+3/$'QJA'[0/Q&A6&>Y7Q!!+9_#?3+W:CM#I?@Z.51K<,;!HVN?
M%TVI0WR@70T;3I6$<?Z=?LX?LV_"C]EGX7Z-\*/A%X?@T7P_I<4<E_?/'&^N
M>)]::)$O?$?B;452-]3UG4&C5IIF6."WB6*PT^WL].M;2S@]\KER'@+!X:7]
MIY_+^V,[KS]M6JXJ]6A1FUK3A1FW2J)/1RG!_"N51ZW6QLI)TZ"C2HKX>1)-
M[;V[6[_,Y_PSX5\-^#=)M]!\*>']$\,Z):(L=IH_A[2K'1M,M8U4(L=O8Z=!
M;6L**JJH6.)<`=3VZ"BBOT"G"-.*A",(16T814(KTBM$<(5\K?'G]BG]F+]I
M?3[JT^,'PA\(>)=0N$D2/Q5;:<FA^-;%GSB:R\7:(;#7HVC<^:()KZ:RF<!;
MNUN8=T3?5-%9XC"X?%P=+$T*.(IO>G6I4ZL7L]IQE;;I;S*4I1^%M>A_'G^V
MQ_P1'^*OP(BOOBK^RUK.O_%?P/H[G5KCPBZB+XL^$(K63[6+_2'TE;6'QC;Z
M>88Y_/TFWT_Q)`(T:#1=0%JUV/6?^":__!9G7/#.IZ'\!?VQM<GU3P]/<6^@
M^$OC1K#,-9\,7:SBU@TCXF2R+YVJ:.96%JGBV=?[5T615/B-KRQ%UJ^E?U9U
M_.;_`,%=O^"6.D^.]#\2?M2?L[>'H['XCZ3;WOB#XK>`=%M&6W\?Z7;0M-J/
MB[0-/MQY</C/355KS5[&WB8>++);RYC@F\3`_P!N?F&<<,8WAFN\_P"$)SIJ
MG=X_)K.>&Q5#3G=.G=*\%=VMI?38]"CB(XA1P^*]Y.RA5O:<'=7MH][1O?LK
MG]%%G>6]_;PW=K+#<6US#%<6UQ;RK/;W%O.N^">"9/W<L4T166.2,M')&ZNC
M,C!C:K^8O_@B+_P4,O=1FL?V,OC%K4E[>16D\GP)\2ZM=%[B6TTZVDN+WX97
MMY.3).]E903:AX->9G=+&VO]`1UBM-`LJ_ITK[KA[/L)Q%EE',L+[JG>G7HM
MWEA\1!+VE&3LKN+:M*RYK['%6I2HU)0ETUB_YH/X9>5UZA1117N&04444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%4M1U"UT
MNRN]0O9DM[2QM;F\NIY#A(;:TA>>>9SCA(XD9W/8#N>*&[)OMJ!_)1_P7N_:
MGO?&WQ;\)?LI>%[^:7PY\,(-/\6^.[6TD<KJOQ#\36(DT'2YXXR?M`\.>$]0
MMKBW5-V;[Q9<0E!/IL;)^XG_``3"_8YT_P#9!_9F\.:)J>G0Q?%;XA6VG^./
MBOJ+Q1_:TUO4+19M-\)^;R_V'P7I\XTB.'>T#ZK_`&QJ,(5-1"K_`"_?L7Z+
M=_MR?\%3]%\9^*H#J.CZ_P#%WQC\=_$T%WNN+>'0_"][J?BO0]'N$<.K:;]N
MA\,>&%MG`C2QECMEV(I$G]T-?E7!-&.?YQG?%^)]]SQ=3`97?_ESAJ+?-4C%
M_!4=XJ,E=KWM>WH8J7LJ5+#1O%J//55[W<K./W6EU>^R"BBBOU4\\****`"B
MBB@`IK*'!5@""""&`((/4$'J#QD=\4ZB@#^(_P#X*M_LPZG^Q+^U[H'Q>^$/
MVCPIX0^)&KK\4_AU?:1"+.#P?\0_#^JVNI>)M!TU8<1VT6G:Q]@\1Z5:C;:0
MZ9K::1#`UIIL\:_UL?LB?M`:3^U!^SM\+?C?I:06\OC/PU:S:]IMNY:+1_%N
MER2Z/XNT=-Y:58M/\1V&I0VC2_/<:>+2\`V7",WQ+_P6M^"5I\7/V&O&OB&&
MT6?Q#\%M8T7XGZ+,L8:X2RLYQH'BR`2A#(EH?"VN:GJ5PB.BM=:183,<V\>/
MB_\`X-X/B_/JOPR^//P0O[LR+X)\5^&_B%X>BD<DQV'C?3;S1==M(.HCM[*^
M\(Z?>2*#L,^N22`>9)(@_*,KI+AOCS$Y13M3RSB'#O&X>A'2G3Q4'[1."3?_
M`"\I5Z7V;I*7D=]1>WPD:TOXM&U+FWNDDKVZ7T^X_I"HHKF/%7C'PEX*LH-2
M\8^)_#WA33KBX%I!J'B36]-T&RENV1I$M8KK5+FV@DN9$CDD2!7,C)'(X&$-
M?JLI1A%RG)1BMY2=DM;:MZ'`=/17'>%OB#X&\<"]_P"$,\9^$O%ITXQ#4/\`
MA&?$>CZ_]A,XD,`O/[*O+L6IF$4AA\\QF4(Y484X[&E3JPJQ4Z4XU(/:4)*2
M??5=5V#5;H**Y+Q9XX\&>![>SNO&?BSPSX2M;Z:2"RN?$^OZ7H%O=SQ1B66"
MVGU6YMHYYDB_>M%$7=8U+L%0%AI^'_$>@^*]+@UOPUK6D>(=&NS*+35M"U*S
MU?3+GR9I()A;W^GS7%I,89XI(91%,_ERQO&V'4J!5(.3@I1<XI.4$TY*^UUO
M;SL!M44458!17+>*O&G@_P`$V/\`:?C+Q3X=\*Z<IYOO$>MZ;H=IGT^T:G<V
MT))P>/,SQQWKQ#_AL;]D[[7]C_X:2^!@N=VSRO\`A:O@G?YG_/,#^U\;L]LB
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M`R)/):1ZM>6CW"0O(B3-"KK$SHKE689Z+1]8TS7].M-8T74=/U?2=0@CNM/U
M32KVWU'3K^VE!,=Q9WMH\MM<P.N"DL,LB,<@'CG.-6$I2@IPE4A;GC&2;C?:
MZW5_-`:=%%%:`%%>3:M\>/@KX>U2^T/Q%\7/ACH&M:9/]FU#2-9\>^%M,U2Q
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MLY9K<3121&:)602(Z%@RFIE7I1@JDJE.-)KXY227E9O3\;AJ]$KL[NBO(O\`
MA?\`\"_^BS_";_PX_@__`.7%'_"__@7_`-%G^$W_`(<?P?\`_+BLOKN#?_,3
M0_\`!D/\_/\`/LQV?9_<>NT5Y%_PO_X%?]%G^$_X?$;P=_7617J=G>6VH6T%
M[93P75G=0PW-I=6TJ3V]S;SQK-!<031DQS031.DD4L;/'(C!D9E(-:TJ]&M?
MV56G4Y;<W))2M?:]GI<+-;IKY%JBL;7_`!#H?A72;S7O$FL:7H&B:=$)M0UC
M6]0M-*TNQB:2.%9;S4+Z6"TM8FFEBB$D\T:&22.,$NZ@X?@_XC_#_P"("W[>
M!O'/A#QFNE-;KJ;>%/$FC>(1IYNUE:U%\='O;P6IN5@G:W\_R_/6&0Q[A&^'
M*K3C4A2=2"J34G&FY)3DHVNXQW=KZZ=4+7>VAVM%%%:`%%8FO>)/#_A>QEU3
MQ'KFCZ!IL*LTNH:WJ=EI-C$%`),EW?SP0(`,DEG``')%>!S_`+8G[)]K=M97
M'[27P.BN4?RVB;XI^"PZ2#JCC^U\*PZX)R?;'//6Q>&P[2KXBA1<KV56M3IM
MV:O93DF[73=MM+[C49/:+?R\[=OZ_+Z7HKA_!_Q+^'OQ`@:Y\#^.O!_C&!55
MVF\+>)=&U^-5=2Z[VTJ\N@GRC/S8..O.:[BM*56G6@ITIPJ0>TJ<E.+^:T%J
MMT%%&:\*\:_M-?L\?#2\?3_B!\;_`(4>#K^/?YVG^(?'WA?2[^,I@L'L;G48
MKM6`/"-"';LO:HKXFCAX\]>K2I0M=SJU:=**U2WG*.]^E]M;#LWLG]Q[K17R
MII?[</['FM3K;:9^TU\#+J=F"+&OQ*\)QLSE@JHOG:I'N8L0!MSCN1QGZ,\.
M^*_#/BVQ34_"WB'0_$>G2*K1W^@ZOI^LV3ALD%+K3KBX@8'!Y#X/;-10QN$Q
M+:H8G#UG&UU2KTJK7->UU"3:O9VOO9V\G*$H_%%KU3\O\[&_111742%?.G[7
M.M77AS]E3]I?Q#9,4O-!_9^^,FLVCJQ1UN--^''B*\@*,I5E(FA7Y@<JVT@U
M]%U\\_M9Z#=^*?V6OVD/#%C&\E[XC^`GQ@T*TCC4M(]SJOP[\06-NB*.2QEG
M`51RSD+CFN+,?:/`XM4OXCPN)Y-]_85-K>=BZ7\2G_CA_P"E(_F`_P"#>70+
M6^_:C^,/B&50UUHGP,NM/M&."8QKWCGPBUQ)'D':^S2$BWCD)*Z\ARI_L%K^
M//\`X-ZO$EKI_P"U3\6?#<SJEQXA^!M_>V>XJ/-E\/\`C?P>98$R03(8-5DG
MV@_ZNWE<\(2/[#*^)\,'3?"F']G_`-!>-YO7V\[7\_TM<ZLP_P!XEOLM[[67
M?\?0****_0SB"BBB@`HHHH`****`/!/VHO#EOXO_`&;/C]X6NH_-@\0?!7XI
M:1(FSS&QJ'@?6;=7B4Y_?QR2+)`P!9)51DPP#+_+'_P;W:Y-:?M;?%+P\&S:
MZ[\`M;NY8R[*&N-$\>>`C;2A1PS1QZE=*&;E5E<#AVK^I/\`:N\3VW@O]F']
MH;Q9=R".'P_\$OBEJG+;#)-:>!]::WMU;(Q-<W`BMX.03/+$!R0*_ER_X-[/
M#\UY^U=\6/$VUA:>'_@-JFGRRB/<JW7B#QWX(:UBWXW(TD.CWCJ`PWK#(3G9
MD?F/%.O''`ZI6]M[;%>UV_A<M7V3^7[S^D=^%O\`4\7?;DBOGI_P#^Q&OY\?
M^#B$X_9I^".!U^.A'.?^A!\6_AZ]O_K_`-!U?SW_`/!Q'_R;3\$/^RZ'VX_X
M0'Q;WKWN/7;A+.GVPJ\O^7]$PPG^\T?^OB/Y^_@'XF_::_8HL/A)^VC\,&D3
MP'XYU7Q%X5NI@+JZ\*ZY-X;U:YMM;^'7Q!LHU1(6U6PM(M:T6X:16"R?:])N
MXM4TB\6V_M4_8R_;/^%'[:WPLM?B%\/+Q-/UFP6VLO'G@*_NHY/$/@?Q`\;/
M)87\86(W>F7/ER3:+K<,*6FK6BLP6WO(+VQM/S'_`.".WPI^'_[0?_!,[Q1\
M(_BGX?M/%/@K6_BO\1M%U33;I2DD?F6OA?4K/4;"Y7][IVK:9>SQW^EZC9F&
MYL+V"WNH&$J;V_(?XX_`K]IS_@CG^TGHOQ6^%FKZCK'PQU74I[7PCXRGMII?
M#GC+PW,\EU??#/XH6%JT5O#J\=K%ND53;K>O:P^)_#,UIJ=HT&C_`)_D=;,^
M#LNRO.*,:N-X9S+"8;$9EATW*MEV)J4XPGB*2L[J;BG**Y5-JS:Y=>ZLHXJ=
M2$K0Q4)\B<I6BZ:LE'LW'5:VL?I;_P`'&5N[_"_]F6Z$:E(?'_CV!Y"061KG
MPYHLD:A3@L'^QLS*O4QJ">:^X/\`@B8<_P#!.OX/'C_D8_BN!CIQ\3O%G?\`
M'GBOR-_X*L?M9?#7]MO]A_\`9U^,WP\F-GJ.@_&:?PYX_P#!EU<)-K'@3Q1J
M_@'6=0.E:DBK%]HT^\;1)Y]`UP116NJV,;R)';WL%_I]C^N7_!$S_E'7\'L=
M_$GQ9QQ_U4[Q9_D^]>OD^*HXWQ*S#%X:I&MA\3P]0KT*D7>,J526`Y9+JF[-
M--::Z[F56,H8)1DK2C7Y6O2.OYGZQU_/)_P5:_X*S^(_@!XEU']G#]G*:QM_
MBC8V<7_"Q/B'<P0:G%X&?5+)+NS\/^&K&=9+.Y\4_89[:\U#4]0@N;#1DNK:
MVAM;K53<IIO]#=?Y\_[:.C:QX`_X*$_'C_A9UM<RI!^T;KWBO4X[N.25M4\'
MZ[XP?Q9HUW#$Z@SV&I^$-4LWM((\0&WD6TCV*&">KXD9SC\JR?#4\#5>%>8X
MM8.OC(KW\/1=.4Y.E+_EW5GR\L*FO+9M)LRP5*%6J_:*\8P<N7O:VA^W_P"S
M#_P1T\3?M":)HWQU_;^^+GQ2\6^,/%]C9^(+3X>1^);MM0TO3-307MK;>+/$
M>L?VG?VU_+'*'NO#V@PZ;%H^Y+-K][B&6*W_`$$G_P""+7_!/*;2_P"S5^#6
MIV[[`G]J0?$7X@+JF1T<SR>(Y(&89/RO;-&2>4QQ7Z>Z#K>D^(M&TO7]!O[/
M5-"UK3K'5=&U33YX[BPU'3-1MTN;&]LYXB8I;6ZMY(YK>2-BLD4B./O5L9KV
ML#P=P_AJ$(3P&'QU5I3K8S'1^M8K$5&O>JU*M64VW+HEHO,REB*SDW&<J:;T
MA!N,8^22V/RZ_9G_`."2?[,O[+/Q;?XO^`-7^)^JZO:P/%X>T7Q+XM2;0=`F
MF5HI[M;;1]/T:;6YC`[P6\7B";4[*U5S-':F[2WN(/U%HS17N8#+L%EE%X?`
M8:EA:#DY^RHQY(*3W:2[F4YRG)RD^:3M=]7;T/PG_P""O?\`P4Q\2?LI6^B?
M`WX(S6=M\9O&7A__`(2'6O%MQ#%?K\._"5[=SZ?93:=8W$<MG<^*=;FL]0>Q
M.HQR6^CZ?:?VA)9W,]]IY3Y-_8B_X)13?M?^`_#_`.U'^VU\4_B?XUO?B1`?
M$OA7P@OB:[&HW/AB^D=]-UGQ-XEU-=0U"./6XE-_I>CZ`--2RTB>QD>_,L[6
MEK\&?\%RO#'B+1/V^?%NM:Q!.ND>,O`'PXUKPG<.K^1-I-AX>A\,7T5NY&S]
MQXAT35R\2L2AN$9@/.0M_5[^P/XPT/QQ^Q=^S)KWAV:";35^"?PZT%Q;NC);
MZMX4\.6/A;Q!8N(P%6>QUS1]1L[E,!EGAE!`Q7Y;E\'Q/QOGN$SN<J^"RA2A
M@<M<JD<)-1J4X>WK4HS@JM5*2;E).^R25ST:D5A\'0J4G:I62E*HOB5U=)/I
M;7U\GO\`.$G_``1@_P"">$E@+#_A25\A"&/[<GQ%^(8O^A7>)CXH,8<9SE8`
M#W7IC\I/VYO^"7?B3]A_P;J?[4_[$OQ6^*'AK3_`CV^I>-?"W_"27,>OZ)HL
MES%`->T37])73Y=6TC2[B>$:QH^N6]T\.E//J,M]>6]I=6LG]5.1TR,U\G?M
MV:GHND_L8_M27GB"6UBTL_`/XJ6<ANF41R7>H^"]6T_3+90S*LEQ=:K=65M:
MQY!>YFB4?,1GZ[.^%,BJ9;C*E'`8?`8BAA<16P^+P,%A*^'JTZ?/&<:E!TF]
M8)>\WULUUYZ&)K*K!2G*<92C%QFW*+NTM4^W0_-G_@D7_P`%-_$O[5[:O\"O
MC>;&7XQ^%/#A\0Z'XOM(8K"+XB>&M.N+6PU'^T+"!([.T\5Z3+=VMS=_V;'%
M9ZKIT[ZA%9VLEC?;_P!V*_AQ_P""'^DZQJ7_``4'^'=YIB3-9:%X*^)VJ>(7
MC4E(](F\'W^BPFX(&%A?7M6T6$$G!G>%0"S+C^XZN/PXS?&YQP[&MCZGMJV&
MQ53"*NU[]:G3ITIQJ5']JHW4<9S^TXW*Q]&%&ORT]$X1E;M>^GW+R]#^2?\`
MX.*?^2W?L[_]DK\2?^I:?\]_Z5^]?_!,C_DP?]EK_LE6D?\`I7?U^"?_``<4
MY_X7=^SQ_P!DL\2?^I:?RK]Z_P#@F0<?L#_LM<@?\6JTCK_U]7]>1D#_`.-C
M<6_]@D?_`'2+K/\`V&A_U\?_`*2OZ_X-C[NHHH!STY^E?JIYY^,__!3W_@EQ
MX9_:[T.Z^*GPJM-/\-?M&Z%I["*XQ%9:1\4=/LHQY'A[Q/)M\JVUNWA40>'?
M$K_/`_D:?K#S:0L4VF?DA_P36_X*6>-?V//&;?LH_M71:[I_PSTW7KGPW97O
MB2"[3Q%\#_$*W<EM/87\$X>YD\#_`&MR+VSC$DF@.\^K:6'TMY[63^P>OQ*_
MX*\?\$\OA_\`'SX3>./VC/#,=EX2^-'PD\$:[XNU+6H+=8K'X@^$?!VDW&L:
MAX?\211+NFU>UTVPG'AO6CNN(&C31KWSM,FA^P_G7$W#V*P6)_UHX:?L,UPU
MZN.PW-:AF6'BDZD94TN66):NE)_'?75*_=AZRE'V%76.GLWU@V]?6^F[5K?=
M]Y?M7?ML?!G]DGX/)\7/&^MV>KV^NV@_X5WX<T&_M;O5?B-JMQ;+<Z?:^'7C
M:2!],DBFM[J_U]BVF:=I\\5R\TLMQ96MW_++\*?A3^T[_P`%H?VFM5^)/Q)U
M6^\,?"/PU?Q6?B#7[2*4^%OAYX8$PNK3X>_#FSNE:WU'Q3?6I26>:4,Z_:!X
MB\1-(&L;"^^6OV+?@CXZ_;^^/WPI^`7C3XF^(8/!?@7PIJLT=SJ%]<:K<^%/
MAOX>O&U;4?#O@RTNWDM;*ZU&_P!3BM+(.AM;(W1OI(9K73+>Q7^[/X._!SX=
M?`3X>^'OA;\*O#5CX5\%>&+-;33-+LD^=W.7NM1U&Z;,^I:MJ5PTEYJ>J7CR
MWE_>32W%S*[L37BY?+'>(]6&+QJ>!X:P-:,?[/A6A4JX_'4X4YRAB90:3HP<
M[.$DE*]T^AI44<#>G%<U=QE&4WHHI\MK+WNSO[RU[E/X'_!#X;_L[?#?P[\*
M/A1X=M/#7@WPU9I;VEI`BM=7UV0/MFLZQ>X$VJ:UJD@%QJ6I71>>YGR25C$<
M:?,G[4__``3?_9E_;%\9Z#\0/C7I'BN^\3>&_#,?A+3KKP[XLO\`P_;_`-B0
MZIJ.L0PW%K`DT$TT=_JVH2I<!$E*7'E2&1(H5C^]J*_4*^68#%82.`Q&$H5<
M''V?)AITTZ,?9?!:']V_?4\^$Y0DIP;C);-'\[O[8'_!'/\`8N^#7[+WQV^*
MG@;1?B%9^,/`'PT\2^*_#L]_X\O=2LHM5T:Q>[M&N;*XM/*N86>,1S1,5+PL
MZ*Z%MU?DU_P2%_8P^"O[9WQ.^+?AGXV6GB.]T?P7X%TC7=&A\.Z[-H,HU+4=
M?33Y);FXMX999HTME94A#1KF1F))"[?ZMO\`@HG_`,F*_M5_]D0\=_\`IEG^
MO3_.*_GZ_P"#=7/_``NW]H<#`_XM?X8_'_BK#[C./_KU^39[D>44>.N&,#2R
M_"TL)B:-=U\/3I*%*KIB6W*":3U^Y]SU*%:L\%B).I)RC.*@V[\NBO9:*[NO
M2WF?J(O_``0J_8"4_P#(N?$[&1N4_$G5`&`(.UL6P8`XYVE6]"*_7?PYX?TO
MPIH6C>&M"MDL=$\/Z5I^B:/8Q;C'9:7I=I#8V%I&SN[LEO:P10H78MM09)/-
M;=%?JN!R;*LLE4GE^`PV#E5BHU'0IJ#G%;*5M[:V[-MGFSJU*EO:3E.VUW>U
M[?Y(_,W_`(+#?\HX/VD.W^@_#/\`'_B\GP[X_P#K?_KK\F/^#<9BVO?M:\#(
MTOX*GZ_Z5\3AZ<=?2OUG_P""PW_*.#]I#/\`SX_#/MT_XO+\.O\`/;^A_);_
M`(-Q,_V]^UM_V"_@K_Z5_$WM_P#7_E7Y[G'_`"=#AW_L5S>_][&;?=M^IVT/
M]QQ'_7V'_MA_4W7XD_\`!5G_`(*AS_L>IIWP<^#UMI6K_'7Q-H@UR[U75(UU
M#1_AMX=O3-#I^IW6G`[-2\2:K-:W,FCZ7=$6=I:VXU;4X;N&?3[#4/VVK^$3
M_@LGX:\5^'_^"@_QKO\`Q/#=K:^+(/`WB/PG>W"R""_\,'P/X?T.V:P:0`-:
MV&IZ+JFCE8U5$NM/N$PS[G?V/$7.<?DN0JKE_-"MBL53PDL1'1X>G.G4G.I&
M6\*C5/EA-)\MVTF[(SP-&%:ORU-8J$I6=]6K::-=S]&_V2/^"9OQ<_;V\,Z+
M^TY^W1\<?BEJN@>-8_[;\$>"8=9;^WM4\/7,C266MW=SJ<-YI'@_0]5C!N=%
MT30-$2:;2I;2_%QI\-Q#`WZE6W_!%G_@GE;Z9_9S_!O5+N39L.J7?Q%^(+ZI
MR!ND6>/Q)#`DC,-WR6RHI)"QA>*^T?V5/$_ACQC^S5\!_$/@RZLKKPU?_"+X
M>_V4U@8O(MX;7PKIUD]@T<3%;:XTZXMIM.N[)@LUE=6TMI.B30N@^A-P]1^8
MKLRCA/((X##5*N%H9I6KT*-6MCL;?&5L34G3C4E4=2M.>[E9**C\*NVU995*
M]7VDN6<H1NK0@^6,>UDMORTT/R3^$7_!&3]DKX*_&/0?C#X-O_BMY_AJ<:AH
M_A#4O&SOX=M]7CDWVE]<7&FZ=INOZA#9N%DBTV^UBXL9W51J$5[!N@;];:,T
M5]%@,LP&5TZE++\+2PM*I4=6=.C'EBYR5G*R[V,YU:E2W/)RY=%?I??\C^9K
M_@N[^U5^T5\,O$/P\^"7P]U+Q-X`^%?C#P5/XC\1>,_#TEUI=UXXUV34M8TV
M^\%CQ%9-'/9Z?H6FV-EJ.IZ597%I-J1UV#^T/-T];=)>7_X)D?\`!/C_`()[
M_'SX,>&?B#\1_&<7QH^+^MQ75YXR\"7OCVY\-MX(OWO[F)-&E\+Z/J&E>(;M
MFMD@F;6]2O+JQU8S_;-+$5LX#?T?_%KX-_#'XZ^#[WP%\6O!?A_QWX1U`$SZ
M/X@L(KV&.<*5BO;&8[;K3=1MLE[74M.GM;^U<;K>YC8DU^'GQ8_X-^O@OK.O
M7'B'X%_&?QW\('DD:>#0M2L(/&^G:=(SE]FE:D-3\/\`B&WMTR-D=]J>J7(P
M#]KQD5^=9QPUF\.(*N>1PF&XFPE6+A2RS'5U1>`C-1O]6A55:A6Y;)RYZ5Y+
MELJ;OS=5*M3]BJ3E.AROXH7ESWM\2TVMW>[VZ_7?BG_@B[_P3U\36#6EK\']
M3\*3E75-2\+^/_'%M?1,P(#JNJZ[J]C(5RQ5+JRN(B<%XWVC&+^S%_P2`^"7
M[+/QLMOC#X)^*'QAU:WTNWF.B^"-6\106&C1ZG-F)+[7+GPU!HDGB>UM;=C'
M:Z3JMNU@9=D]]'?F&!(_SDU7_@F-_P`%4O@'9/JW[/7[8>I>-K?3%-Q:>&8?
MB!XR\*W=W'#E_L\&@>++C5O!]S)(%!^QWVKP6DN2LA;Y$D\R_9S_`."U_P"T
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M!_=."",@@@\@CD<\C\QS7\GG_!?;]E"]\.^//!W[6_A;3G;1?&]O8>`OB=+:
MQMBP\7:';N/"7B*\:(%PFO\`AVW30O.9T%O=>%],B+F748Z_7C_@E!^VA8_M
M9_LUZ-9>(-5BF^,7PCL]+\%?$BSGF5K[5(;2U-OX8\<>6S>:]OXITVS+7LY1
M5'B&RUM?+BA,`;\JX-K1X>SS.^$<1[D98J>892^E:A6^*C"3MSU+*#A&]W:2
MT:U]#$Q]M2I8F+YGRJ%9V^&UE!OKK>6MO2Y^IE%&:*_53SPHHHH`****`"BB
MH9YXK:)YIY$BAB1Y9997$<<44:&22621B%1(T4L[,0``22`#1>WY@?CQ_P`%
MP?CE9_"O]B7Q!X)MKQ(/$_QR\1:)X`TFW279<_V)9WD'B?QA>^6I#/9#1]'7
M0;OHC3>(K.W<@3\_+_\`P;S_``=N-"^#OQL^-^I6C12?$7QGHG@GP_+-%M>7
M1?A_I]Y?:C>VY))>"^UKQ;+I\Q)*F;P^8L?N2S?D_P#\%)_VD/$'_!0G]L[0
M?AS\&XYO$O@_POK-M\'_`(/6%DS2VOBG7=7U:WM?$'C&!AN2.U\0:N8(K>^;
MRUC\*>']-U&Y\L-=1)_87^R_\"M"_9I^`OPQ^!_AUEGLO`7ABQTN\U!(_*&L
M:_<M+J?BC7#'U1];\1WVJ:JT;$M#]J$(.R-57\HRBHN)>.<7GD'SY7D%%X'"
M5EK&IBIM4ER:+[53$57NUS1CMJ=]5JAA(T6VZM6U1QT22=G:]W?9=%?LEJ_H
M*OQ5_P""W'[//QH_:*^`?PG\._!/X?:U\1-<T#XNIKNLZ7H9LOM=AH[^#O$N
MG?;WBO+JV\R!;R[MK<^2797GCW*`<U^U5%?H><Y71SK+<5EF(J3I4L72]E.5
M-0YTE.$[QYXR7V+=-'Z')2J.E.,TKN/38_(__@C#\$/C!\`/V4/$/@7XT^!-
M:^'OB>?XR>+/$%AHNNM8F\FT/4/#7@JSMK]5L;N\5(9KW3=0A02O'(QMV?RP
MK+7Z3?%WX1?#[XZ_#_Q%\+_BCX<L?%7@KQ38O8ZMI-\G?*R6U]97"XGL-4TZ
MX2.]TS4K1XKS3[V&&ZM9HYHD<>E9HHP&4X7`97ALH2]OA</AHX7EK+G]I22M
M::>]_5V%4FZE24[)<TG*W17/XE/VI/\`@CG^UI\(/B-K_A7X&>$?%/QL^#VN
MW4.MZ!J^@7&G1WD,-H;]-,TOQKI$U]8I_P`)'H*7MQ;VNIP6TEAJ%I<SWM@U
MG<7E_96?])?_``2B^$OQ(^"'[$'PO^''Q6\)ZCX)\;:1J_Q%O-3\-ZLUJVH6
M,.L^/_$FJZ>UQ]CGN8%^TV%W;74:"7>L<R"5(WXK](**\#).",KR#-<1F>7U
M<5#V]*=%86I4=2A0ISJ4JCIT92O55-.E:,)SFH\SY6M4]JF)G5IQIRC%*+O>
M*MTM:R"OR]_X*`_\$Q?A7^W!IMCXB;4W^'OQIT#2SIF@_$/3[%+RVU33H6EF
MM=!\8Z2LD!U72K>:>5K*[MKBVU;3#+)]FNI+=Y+.7]0J*^ES'+<'FV%G@L?0
MAB,-4^.G.*=G]F<&_@J0UY)K6-WW,(3E3DIP?+);,_E^^$?P_P#^"S'_``3W
MM!X$\&>!?#W[2_P:TN9_[&T&TUB+Q-8:7:/([!?#<4^I>&O'OAZ*0+YK:0MI
M?:+9SR/)!:2,QD;ZFL/^"D__``4+O4.EQ_\`!+7XD'7U0(TLFM^)+#1C*2,,
M)KSP5$BQ;26(.HY4?(6;;NK]VZ*^<PW"N)R^G[#+>)LZPN%3_=X>K'+L=&A'
MI3HU,;@JU6%.*T4>=V[Z*V[KQE9SI0E/K*-X<VVZ5T]E\[L_(CX`?%;_`(*P
M_$#XMZ!J_P`8/V=?@K\*_@?.?LOB+P]?^+#'XR@L)Y8V76M)O=-U;Q=>7>L:
M=&69=*U#2M*TV_#S6D[:=,8;VW_7>BBOH<NP-7`494JN88[,92FY^UQTZ,YP
MYMX4_8T:/+372#YN7H]7?&<E*UH1A;^56OMOZ6/AC]N3]A#X4?MP?#RS\+>-
MVNO#OC'PR;V[^'_Q%T>VAEUGPQ>WD`BN[6X@D,46K^']26.%-4T:>:`2B*.X
MM+JRO88;I/Q@^"?P9_X*S_\`!,Z76_!GPP^'7A?]I_X'7^KS:O'H.D:F+Z"U
MNIMB3:EHVF37^B^,/#&IZA''$VH65M9:]H32H)O*N;A7GD_J&HKR,SX5P&88
MV.:4:^*RS-H+E_M#`3A3JU(:7IXB%2%2E7I.R]RI%I=&KLTA7G&*IR4)TD[J
M$HZ+T:>A^&"_\%.?VY8X?LUQ_P`$K_C*VK@^47AU;Q1_9WV@Y^;S#\.)/W(;
M;EA<,I!)#\8/RA\>?!/_``5V_P""D=E:_#;Q/\%O#_[,GP0GU.UOM6TS7M:C
MTM-3^PW,=S9/XIN)KS4_&?B*/3I<7MEIVF>'-,TF74H;2YN+3S+6.X@_I^S1
M7/B.%\3CJ,L+F7$6;8O!U&O;8:G#`X*->*T]G6J8;#0JSIR^U!3BG^`XUU"2
MG"E!36SE>=MMD]%M_77\XO\`@G]_P3F^&G["OA+5#IFI2>-OBOXPMK2+QS\1
M+RT6R\^VM9!<P^'O#>G[YFTCPW!>`W,D,EQ<7NK72Q7FIW#M;6%M8?H[117T
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M,:4H0FH_#)K57M?3;H?@A_PW)_P6`_Z1O:-_X,]:_P#FKK];OV9/&?QD^('P
M5\(^+_C]\.].^$_Q3UJ/5Y_$'@#2[R6_A\/P0Z[J=GHD<T\US>.+R^T2WT[4
MKNW-S,;.>\DM)&2:&2*/Z!HKV,MRG&8&M.KB,\S',HRIN$:.+CA53BW;WTZ5
M"%2Z2LDJD4^J>ELYU%)65.$._+?7;>]^S^_[RO!?VH/#6N^-/V;?C]X-\+:;
M-J_B;Q;\%OBEX9\/:3`T:3ZGKNN>!];TW2=/A>=HX$FO=0N;>UC,TL46^5=T
MB`YKWG(]12UZU>C#$4:M"I\%6G4I3MI+EJPE!V?1^]==[6,T[24NS_5/]#^4
M;_@CQ^Q+^U7\!/VOO^%@?&+X)>+?`'@^'X6^-M);7M>.E1VC:GJ-SH'V*QC%
MKJ-U,\]PL$[J!"56.&1W9<#/]7-%%>1P[P_A>&\O>78.I6JT77JU^:MR.?-5
MY;KW(Q_E6KO?R-:]>>(GSRT]V,;+RZW\_P``HHHKW3$^5/VW_!GBKXC?LB?M
M$>`O!&BW7B/Q?XN^$GC+0_#FAV+0K>:KJU[I,T=G86QN)(8/.N96$4?FS1H9
M&1"V7%?B]_P1#_9)_:2_9P^*?QQ\0?&[X1^)_ASI/B#X?^'=)T2\U_\`LY4U
M/4;?Q%)>SVUHMG?7<SRPVZ;W)C6-0Z[I%9D1_P"DRBOGL;PYA,=GF6Y]4K8B
MGB<LISI4J<'#V4XS]I?G4XR::=2_N[VUWTVC7G&C.C'13ES-]=DK6^04445]
M"8GP/_P4Z^&7C[XQ_L-?'/X;?##PS?>,/''B6Q\##0_#FF&W6_U(Z1\3O!.N
MWZ6QNIH(=T&EZ;?7;*\JED@8)ND*1O\`F[_P0U_96_:$_9MU/]I&]^.'PN\1
M?#B#Q?9_"JU\.-X@_L]'UB;19?'LNJBTBLKV\<K9#5M/\Z23RE!G"KN*OM_H
M:HKYS$\-X3%9_@.(9U\1#%8##2PU*E!P]C*$O;7<E.,K->V=K)/17;N;*M*-
M&=%:*<N9RZZ6MIY6"O@G]NG]@'X1_MR>"+#1O&KS^&?'?AB.Y;P'\2='MX)M
M8T"2Y3-SIE_:2M%%KOAN_D"2WNC7,\&V1?M=A>6%V7G?[VHSGI7L8[`X7,L+
M5P>-HPKX:O%PJ4YI--/K%OX9QWA-:Q>QG"<J<E.#Y9+9G\M'PO\`V9O^"O?_
M``3BOM1TCX#6WAG]H;X.-J$^HGP=::E:ZGHDYDEEDEO;3PKKNJ>'/%GA?6+L
M'=>P^$[Z[M+N=UENFU.6,O7UGI?_``4H_P""A\2QZ3K'_!+;XC77B';L:?3-
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MNI65PTN^RL--\*ZQ+!!9I')+<W-U,^SYZT?_`(*/_P#!4+PAY=C\3O\`@FQX
MC\23Q*HEO_!.F^.M*BF9<*[A8K/QU9-O`#((KN*,`G`;;D_T)45Y-?A[&RQ-
M?$X7B7.<+*O/VCI-X;$8>F_Y:5*K1_=TTM(P3TO>[TM<*RC%*5*E*VSY>5].
MWH?SZ^(_^"@__!4CXDZ=+HGP;_X)S^)O`>MW8-O!XD\=PZ]J5MIS3?(ES%;Z
M_8>`]'CDAD"NLNIW-S8J0!<02(<-\]_LP?\`!%[XV_$3XT+^T+^W;XFTU)-3
M\7/\0/$/@#2]2M]>\2>-/$,^H'6'@\6ZSI:)X>T72)K\[;_3M$FU.6ZL5;38
M'T=)0\']1V:3</4?G7+/@ZCCL3A\1GF:8_._JM55J&%Q'L*&#A65FI_5L/2B
MI/2-E.4K6TM=WM8J4(2A2A&CS?%*'QZ;6F]59_?U$50@PH`'```P`````.P`
M``':G445]D<H4444`>5?&WX-^!_V@/A=XS^$'Q'TX:KX,\<Z'=:+JULH1;FW
M>4QS6&KZ;.Z2?9-7T34(+;5=(NPC?9=2M+:XV2&(+7\2FIV'[1O_``1]_;+2
MXME>\M]/FG;3KJYBN+/PA\:?A->WRO+;3$-,J2F&UC-W`KS7_A/Q;81W$*3P
MV5K>7W]X%?*7[6_['_PB_;(^%]U\-OBIICF6#[1>^#_&6F)%'XH\#:^\6R+5
M]"O&C<^6Y$<>IZ7<>;8:M:@0WD+216]Q;_$\7<+SSFGAL?EU;ZGG>63]K@<3
M'W?:-<O[BK)._++E]V5GRW?NV9U86O&C.4:BO2JQY)I>NC\[79:_9._:X^$/
M[87PNL/B9\*=9BE'EVUOXI\)7L\*^*/!&O21;Y]$\0V*L7A=2LC6%_&K6&K6
MBB[L9G0R)%]1U_"=\5_@%^VW_P`$E/C+#X^\*ZSK6F^'S>&S\._%OPI:7-Y\
M/O'.DM,)HO#_`(TTBX^TZ?:75U'!`+[PGXE1BUW&UQH-_?FVM=37]K?V3O\`
M@O/\$?B'9:9X8_:;T.X^#7C1EBMY_&6CVNH:_P##36+DA(Q>&.TCO/$OA8W4
MS`"UN[/6-/M@=\^N10CY/-R3C[#N7]E<34Y9-G.'E[*H\4G2PF(<4KU57<52
MI7T?+*5GS>[)V=M*V":3J8=QJTGK%0=W%:?%UUNNG?Y_T"45YO\`#CXO_"WX
MNZ2NN?##XB^"?B#I+I'*+_P=XFT?Q##&DJAD%R-,NKA[27!&Z&Y6*9#P\:GB
MO1\CU%?HE*K3K0C4I5(5825U.G)3B_1IM'#KV%HJ.6:*"-Y9I(X8HT:2225U
MCCC102SN[D*B*`2S,0``23BO@O\`:!_X*7_L;_LWV-]_PFGQC\-^(/$EH)5B
M\#?#N\M_'/BR>YCW?Z)-:Z)--I^B3$H_S>)-1T:`;''F^8!&V&+Q^#P%-UL;
MBL/A:*OS5*]:%)*W92:<O.UVBX4YU)*,(N3?9>G^?ZGWN2`"20`.23P`/4D\
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MW.K_`.")_P#P3IOOAU86_P"UW\:=$DL/&OB/29(/@UX7U.TV7WA?POK-J4O?
M'&H03`O::YXGTZ8V>AP%4EL/#=U=7,YE.O+#9?T=U%%$L*A$`"J`J@``*H)V
MJ`.`%!PH`Z`9R<FI:_0,AR3"</9;1RW!K]W3O.I4<;3KUYV]K6GJ_>FTM+NR
M5KO<XJM65:;G+KI%?RQ6T?E\O0*_._\`;^_;AU;]B[3?@O)H?P\T?Q_J7QB\
M>S>!H%\0>+Y/!FCZ`Z6]C(FJ:EJL6B:V%LEEOXOMD\D,:6=I'-<YE9!"_P"B
M%?EK_P`%-_V,?B=^V%I7P"B^&LWPYDE^$WQ*NO&>OZ'\2[[6+'0?$NE/;:<H
MT60Z3H>O--!?267V;4(;FU6)K">;8SR;8GCB*>90RG$SRE2ECX^Q]A&"@Y2O
MB*/M+<\9+6ESQVT4F]TAT?9^TC[6_L_M6W,#XU_M_?&?]G?P3>^/?B)\.?V5
M/$&F:7LEN?#?P]_:]^U>.=3A:XAA,?AGPWXF^$FAMXBU%5EWKIFGW,MW.(Y#
M%&0@W?H5\!_BROQR^$G@7XK)X.\5^`%\<:!:Z]'X1\;V*:=XET>.Z>=(XM0M
M8Y95$=RD`OM/N-T9O-+NK&]:WMS<>0GYA?$W]C3XR_$;P7K_`(3TW]C_`/X)
MS^`M5UG2KS3]-\;6LWBG4]7\+W-RJQIK>B0Z1\&_"U^NL::1]KTN>#7+#[+J
M$5K=%I8X7MY_M[]B+]GKQ[^S%\"='^%/Q&^,.O\`QL\1V&IZCJC>)M<2[6'2
M+345M?)\)^'SJ5WJ&J-X>T=[>:2Q;4;V><R7MR8H[*S^RV%KYF55,[_M.4,1
M#$U,MJ8-252<*-.-+$1:L^=PH5ZKK)O2E1J*GR+GY5)<UU(T^7FA)W3U3](K
MNW?OJ?7U<EX[\3_\(9X+\6^+19_V@?#'AC7O$0L?-\D7IT32;O5/LAF$<IA^
MT"U\H2B*7R]^_P`M@,5UM<5\1O#UWXM\`^-O"MA)!#>^)_"/B3P]:3W)D%M;
MW.L:->Z?;S7!B5Y/(CFN4:?RTDD$08QQN1BOJJZJNE55'2K[*HJ7;VG+[F^G
MQ'.O/8^9?V#?VK[K]LW]GO1_C?>^"X/`5QJ?B+Q/H$GAZWUJ37XHCX=U$V(N
M5U&73M+=ENEQ)Y1M?W1)`=QS7V?7P+_P3;_9@\=_LA_LPZ%\%_B-JOAO6/$^
MG>*?%^OW-[X4N-2N]&^S^(-5:ZM((;C5=,TB\DFA@5/M&^QB1969$R%W'[ZK
M@R5XUY5@'F,91QSPE%XN,DE)5VGSMI72;=M%_P`!:57!U)>R34+^[>^UO,*_
M-"?]O_6OB?\`'WXA_LY_LH_"&W^+GB?X02M9_%?X@^,O'"_#SX8>#=7BU*?2
M+C18KVR\/^+O$GB/4;?5+34-/FCT[084^UZ7J8MWN;:RFN5_2^OR3T3]AGXO
M_LU?M,?%S]HK]DCQ/X`UG0_CS=W&K?$_X*_%]]>T738]?GU:^\1'6/!_CSPQ
MIGB"^TV0:QJNKSV^G:GX:O[2QBU2YM`UU$NGBPY\ZEFD99?]057ZM]:?]IRP
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M/]JX?M9+^QM_PS?\$S\4F\$GQ_\`VN/CSXM_X0A=!^PF[!;4_P#A3G]N?;MP
M$'V5?#Q3S<-]H$&Z6/\`2;X2ZQ\:M7TG5)/C;X-^'G@K7(=16/2+/X=>.=>\
M=Z;>:5]FC+7=_?>(/`_@:>SO#>"XB2R@LKR/[.D<SW2NYA7XL;]D#XBG_@II
M'^V:-9\*?\*U7X*M\/3HINM47Q=_;K6;V9E^Q?V4=+.FJA%R;C^U_.Q^Z^R[
MUW5^E]?/Y)0S+GQ\LPQ.*:I9CB*6#IU%AXPJY?#D^K56J=&+GS>_:HVI22VC
M;72HX>[R-OW4YWZ3?Q+6^VFO7L%>8?&GXA_\*A^#_P`4OBJ=+.M_\*T^''CC
MQ^=%%U]B.K_\(;X7U/Q$=,6\$%T;1K]=--HMR+:X\AI1*8)0A4^GUX[^T!X#
MU7XI_`GXS_##0KBRL]:^(WPG^(W@/2+S4WGCTZSU3Q?X,UC0-/NM0>VAN+A+
M*WO=1AEO&@@FG6V60PPRR!(V]S%^U6%Q#HK]\J%=T?\`KZJ4W#\2(ZRBNC:N
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M0TGPD^A?$KP!\)OARNA26>F>$/#?P<\0ZSKGA:U\-VUC`D,/DZQX-\&)H\MG
M<"6VM]/T^QN+,6<<$BR02,]NGS?#U;-90PL<V6.CBOJK==5J,_8^V3CS-SIT
MEAH/:UJTN;HE9WUK*FI_NG=?ITU]-?\`,]SI"0H+,0``22>``.I)I:BG@CN8
MI(9E#Q2QO%+&P!62.0;9$8$$%73*-QG:QP0>:^L,3\R?!W_!0?7/VD/B%X[\
M`?L8_!NV^+VD?#.]@TOQK\8_'GCF/X;_``KLM3NYK^*UL_#\ECX=\8^*O%AN
MAIE[+!<:?H-K;M;PI>>:;&[L;NY^E/!/BG]KQ_&&E:=\1_A-\"K3P3>B8ZIX
MH\$_&+QG?ZUHX2%WA6+PQKOPETR/5Y)I0D2HNMZ>BQL\TTD1C2.;XJ^!_P"P
M_P#M`?L.>+?B,W[)'BCX6>.O@S\2O$/_``E-W\(?C8WB?PUK?A/5DMVM%7PQ
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M,_9,_;6^'?[2'P`\`?&3Q!K/@/X;ZSXPM=:?4O!-YX^T2ZNM!NM'\2ZSX?:W
MFGO6TFZ;[7'I46IP^?IUK)]FOX/W;KMEE]<_:A^&>N?&C]G7XW_"/PU=Z?8^
M(/B5\+/''@?1KW5WN(M+M=5\1^'K_2K&:_DM+>ZN8[-+FZC:YDAMIY(X5=EB
M=L*?EG]C/]@/X:?!3]F[X:?#+XR?"CX(>.OB3X9L=<3Q5XJC\"Z#XB_M>]U7
MQ9K^N6T@UGQ#X<MM7O\`[)I>I6&G&:\AC<-9M#&@@BCS\WB*F<K.Z,,)&G+*
MWEE1U)5W.%'Z[];A"%JD*=1JKR2ERP<5S*/Q::;14/92<OC<ERVW26^G7FNO
M2W2Y>\$_M[Z5X]_;R\5?L<>'/#.@ZQH/AOX6P_$!/BEHOC&VU>&]U`VGAR]G
MT--)L;&6S06\7B".*2;^VFN$GMV+6@1OE_1.ORI^&?[!.K_"O_@HYXS_`&J_
M!]A\-?"7P6U[X/1^"-,\$^$[&31-7M/$4EKX5M+R]?0=.T2ST"&UN'T&YNIK
MN'4&N9WEB$MOYA+']5JZLDGFDJ6-_M6*C6CF.*C0Y7>#P:Y/J[IRLG*G;FY9
M2C%O6\5853V?[OV:_P"74.;SG9MOROIH%%%%>T9!1110!X/^TQ\89OV??@'\
M5OC3!H">)YOAKX,UCQ7'H$M^=+CU5]-MQ*MF^H"UO6M%E;`:86LQ49VH6P#D
M_LF_'6;]IC]G;X6_'2?PW'X1G^(V@3ZS+X;BU)M832G@U?4](:!-2:ST][I7
M;3S,KM9P$"3RRN4)*?M<?";7_CM^S/\`&KX.^%;S3-/\1?$7X?:[X7T6\UJ2
MZATFWU+4;4I;2:A-9VE]=Q6OF!5DDM[.Y=`VY87P16'^Q/\`!7Q-^SI^RQ\'
M?@EXQOM'U/Q/\/?#=QI&LW^@37=SH\]U<:YJVJYL)KZSL+N2*.*_CB+SV=NS
M.C$1JI6O%4LP_P!8%%0G_97]E2ES\J]G]>CC865[WYO9MNUK6UZ::J,?8\U_
M>Y^1*VMN5._WZ>OR/JNBBBO:,C\/?#/_``67T>W^,WQ2\(_%GX'ZUX&^"WPV
M^,>O_!?4_CMHNN7'BS1_#GB>QUW6M)\.3>.]%M]"M;O0=+\31:%?21:C;W%X
MEE=0RVHAO%M[B:+ZV_;#_;OT[]F71_V<?$/A7PII/Q6\/_M`?$W0_!%CK.G>
M+(K/3;/1-:CLYH/$.D7]CINM6NM?:+:\2>R19;:TEC1F>\4$8\S_`&/?V"_$
M7PC\6?MT?\+PC^'?C[X=?M3_`!4G\8:/X9MUO=;@?PY=Z[\0-3N+#Q7INLZ+
M8VD-VUMXKTM$BL9]3BCN;*6>*[C:.W9OD?XN_P#!(;XOP>,/AMX9^`'QATI?
MV8?"/QG\,?&.R^$OQ3OM>O=5^&.K:7?2-K>G_#?7;;2]9FO]`U?3[FXDAT35
M9M.6#44CNKB[O+M3J4GYU[;C.CE523I5,7BL5BW3I)K#4,3@(QS&-*$I17+&
MOAL1@U[3VSE&I251_NY))OM7U5U%[K4(J\EJ^>Z[KX;/UO?I8_H0HHHK]%5[
M*^_4XC\_OVA/V^?"7PA^,W@S]F/X=>`_$/QQ_:3\>0QW6D?#;PYJFE^'-+T3
M3I;"_P!635?&OC'5_-L=`L_['TS4=9*6]CJMZFEVANI[:!;FS-SU1\9?M[QV
M\.H?\*)_9JN"YB:;P_'\?_'D6IV\4A`>/^UY/@D^FSW$'60K`L4F&\IFXKQ3
M]H+]@SQCK'[4?AK]MG]FSXC:#X%^/6CZ*GASQ'X<^(.@7GB'X;>/]$31)?#A
M@U)M*NK37?#M^^A/!ITVI::]Z98=+TIX+:UO+>YNKWV^V\2?M[2VHL;CX0?L
MN66HA"C>(/\`A=WQ)O-)\Y0H^TKX;3X,6VH&%\NRVS>(%=541M>G<'KY*%3-
M'C,?',98VE2ABG'+EE^&C5P[P.GLW4JRPV)J2Q._MU.48KW>1O7EZ?<Y82I\
MEW%.:J*SC/K&/=+>^[OMH?8>E7%_<Z?92ZK:6UAJ;V=K)J-E97LNHV=I?20J
MUW:VM_-9:;+>V]O.9(H;N2PLGN8U65[2W9C"FA63H;:LVD::=?CL(M<.GV1U
MF/26N9-*35?LT8U!=,DNXX;N2P%V)?LCW$4<[0&,RHLFX5K5]8G=)]TG^'R.
M8****8!1110!S_BCPMX>\::)J/AKQ7HNE>(_#NL6DUAJVAZYI]IJNDZG97"E
M)[6^TZ_@N;.Z@D7`:.>%U.!QZ_AU^TO_`,$&?V<?B?=:AXC^!?B37?@+XBOF
MEN'T.W@;Q=\.7NB6D/V;0;Z\L];T$3RN?ETCQ`-+M(QBVT3"^3)^\M%>-FN0
M93G5+V.9X*CB8QCR0FXJ-:$=-(5E>4=M;67D:4ZU2C+FIR<>ZZ/U1_%-XS_X
M(E?\%!OA+JSZC\,HO"GQ`^RR/-8ZQ\-_B)%X7U=`&58Y&M?%\G@NXMKMD"N5
MMM0OUC`VI+*\88<S'^S]_P`%K?#RC3+2S_;%MXH,*L6E_%+Q/=V2*`%40SZ=
MXUN+)QP3^YD)!/SD_+C^W^BOCI^&.4Q:6$S7/,#3_P"?5#&IPZ6TJ4YVMY6N
MG9WL=*QM3K"G+U@OT/X>)_V`?^"NWQO\NR\:^$_C1K5A*P\Z;XL_&*PBL8U8
M@AIM/\3>.)KYL?-S%IUU*NQ=T;!]I^N/@C_P;U_%;5KNTU+]H+XQ^%O!FEF1
M9KOP_P##6UO?&'B.X0LKFV?6]8M-#T32K@_O,W-O8^)X]SDB*7/F+_6?15X7
MPPX?IU%5QM;,<TDMX8W$1=&=K?%"E3ISZ;1J16KT#Z]57P*%/I[BM?;?^NK/
MBO\`9=_X)_\`[,'[(=E&WPD\`6X\5-;_`&;4/B-XHD3Q#X^U)'7;.KZY=PJF
ME6MSRUQIGAVTT;2Y7+2/9-))([?:E%%?>X/!83`4(8;!8>EAL/#2%*C!0A'T
M2.24I3DY2;E)[R>K?S"BBBNHD****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
7`****`"BBB@`HHHH`****`"BBB@#_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
